Factors associated with post-transplant active Epstein-Barr virus infection and lymphoproliferative disease in hematopoietic stem cell transplant recipients: a …
PR Enok Bonong, M Zahreddine, C Buteau, M Duval… - Vaccines, 2021 - mdpi.com
This systematic review was undertaken to identify risk factors associated with post-transplant
Epstein–Barr virus (EBV) active infection and post-transplant lymphoproliferative disease …
Epstein–Barr virus (EBV) active infection and post-transplant lymphoproliferative disease …
Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality
JL Ramdial, RS Mehta, RM Saliba, AM Alousi… - Bone marrow …, 2021 - nature.com
Despite low nonrelapse mortality (NRM) at day 100 after allogeneic hematopoietic cell
transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively …
transplantation (HCT), NRM at 1 year remains substantial. In this study, we retrospectively …
Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation
S Shiratori, J Sugita, S Ota, S Kasahara… - Bone Marrow …, 2021 - nature.com
Allogeneic peripheral blood stem cell transplantation (PBSCT) is associated with an
increased risk of severe acute and chronic graft-versus-host disease (GVHD) compared to …
increased risk of severe acute and chronic graft-versus-host disease (GVHD) compared to …
Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors
Antithymocyte globulin (ATG) has been shown to reduce chronic graft-versus-host disease
(GVHD) particularly in allogeneic peripheral blood stem cell transplantation (PBSCT) from …
(GVHD) particularly in allogeneic peripheral blood stem cell transplantation (PBSCT) from …
High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease
S Shiratori, H Ohigashi, T Ara, A Yasumoto, H Goto… - Annals of …, 2021 - Springer
Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease
(GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk …
(GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk …
Graft-versus-host disease prophylaxis using low-dose antithymocyte globulin in peripheral blood stem cell transplantation—a matched-pair analysis
S Shiratori, M Kurata, J Sugita, S Ota… - … and Cellular Therapy, 2021 - Elsevier
Antithymocyte globulin (ATG) decreases chronic graft-versus-host disease (cGVHD) in
peripheral blood stem cell transplantation (PBSCT); however, the optimal ATG dose has not …
peripheral blood stem cell transplantation (PBSCT); however, the optimal ATG dose has not …
Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease—an analysis from transplant centers across Europe
R Langer, A Lelas, M Rittenschober… - Frontiers in …, 2024 - frontiersin.org
Introduction Chronic graft-versus-host disease (cGvHD) is a serious late complication of
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods This multicenter …
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods This multicenter …
Diagnostic stewardship to limit repeat plasma cytomegalovirus viral load testing
A Trirattanapikul, E Pasomsub, S Siriyotha… - BMC Infectious …, 2023 - Springer
Background Frequent serial monitoring of plasma cytomegalovirus (CMV) viral load caused
unnecessary budgets for laboratory testing without changes in treatment. We aimed to …
unnecessary budgets for laboratory testing without changes in treatment. We aimed to …
[HTML][HTML] TBI+ rATG 为基础的联合预处理方案单倍体造血干细胞移植治疗化疗耐药进展期外周T 细胞淋巴瘤11 例
徐榕， 李肃， 刘慧霞， 魏道林， 蒋瑛… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
TBI+rATG为基础的联合预处理方案单倍体造血干细胞移植治疗化疗耐药进展期外周T细胞淋巴瘤
11例- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
11例- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
Ergebnisse einer dosisreduzierten Konditionierung mit Fludarabin/Treosulfan zur allogenen Stammzelltransplantation bei Patienten mit hämatologischen Neoplasien
E Horsmann - 2023 - tobias-lib.ub.uni-tuebingen.de
Die allogene SZT ist für viele hämatoonkologische Erkrankungen die einzige kurative
Therapie. Beelen et al. stellten in einer großen Studie fest, dass Treosulfan Busulfan nicht …
Therapie. Beelen et al. stellten in einer großen Studie fest, dass Treosulfan Busulfan nicht …